Healthcare / BiotechnologyHKSE
$1.11
-0.05 (-4.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-465.8M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$801M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.4%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-28.8%
FCF CAGR
—
FCF margin
-2503.6%
FCF / Net income
2.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.6M · net income $-222.6M · FCF $-465.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.6M | $18.6M | — | $617000.00 | $51.6M |
| Net Income | $-222.6M | $-222.6M | $-508.2M | $-174.8M | $-484.3M |
| EBITDA | $-214.5M | $-214.5M | $-501.2M | $-168.2M | $-471.9M |
| EPS | -0.31 | -0.31 | -0.70 | -0.24 | -0.67 |
| Operating Margin | -1541.5% | -1541.5% | — | -88287.2% | -996.0% |
| Net Margin | -1196.6% | -1196.6% | — | -28335.3% | -938.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 60.73 | 60.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-465.8M | $-465.8M | $-376.1M | $-643.6M | $-635.6M |
| Returns | |||||
| ROE | -9.4% | -9.4% | -19.1% | -5.6% | -15.2% |
| Valuation | |||||
| P/B | 0.34 | 0.34 | 0.27 | 0.50 | 1.76 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -98.8% | — |
| EPS Growth | 55.7% | 55.7% | -191.7% | 64.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.70 → -0.31
Residual
-33.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.